BASF SE

DUBLIN--( BUSINESS WIRE )--The "Pharmaceutical Regulatory Affairs in China Training Course" conference has been added to ResearchAndMarkets.com's offering. This seminar will provide an invaluable overview of how to gain and maintain a successful pharmaceutical marketing authorisation in the People's Republic of China (PRC), including Hong Kong, Macau and Taiwan. The two-day course offers a comprehensive overview of critical components necessary for obtaining and preserving successful marketing authorization within the region. It will delve into the recent regulatory reforms and the drug regulatory systems that impact this process. Participants will gain insights into both import and local manufacture registration procedures, alongside detailed coverage of clinical product development, including Chemistry, Manufacturing, and Controls (CMC) regulatory requirements. The course also provides a practical interpretation of these topics, aiming to equip attendees with applicable knowledge. Additionally, it offers a valuable platform for delegates to exchange experiences, enhancing learning through shared insights and discussions. Who Should Attend: This seminar will be of particular interest to all those who need to learn about successful marketing authorisation applications and in-market regulatory compliance in this region. You will find this seminar useful both as an introductory or refresher course. Previous delegates have included scientists and technical staff in regulatory affairs and registration departments, medical directors, and personnel from analytical research and development, clinical development, quality assurance, new business development and regulatory authorities. Benefits of attending: Gain an overview of the regulatory procedures in the region Understand and assess the impact of recent regulatory reforms Discuss clinical product development and Chinese-specific approaches Understand requirements for import and local manufacturing registration Discuss product registration strategies Certifications: CPD: 12 hours for your records Certificate of completion Agenda: Day 1 General introduction to the PRC and the pharmaceutical market Commercial and cultural background P.R. China - Drug Regulatory Systems Regulatory authorities Recent regulatory changes Regulations and guidelines Drug classification systems Import and local manufacture registration Data requirements Registration requirements Labelling requirements P.R. China - Clinical Product Development Regulatory aspects of clinical development Recent regulatory changes Documentation needs including CMC Regulatory requirements including GCP aspects Chinese-specific approaches Multinational clinical trials Hong Kong SAR Background overview Regulatory authorities Regulatory requirements and procedures Specific market aspects Macau SAR Brief overview of regulatory aspects Day 2 P.R. China - Regulatory Strategies P.R. China - Health Authority Interactions P.R. China - Maintenance Taiwan (Republic of China) Cultural background Regulatory authorities Regulations and guidelines Drug classification systems Data requirements Country-specific matters P.R China - Recent Developments Speakers: Mónica Dressler-Meyer DRA Manager Management Forum Mónica is DRA Manager based in Switzerland with several years of regulatory experience. She has spent many years in DRA working with different pharmaceutical companies with responsibility for Asia Pacific and lately also for development activities in other regions. Prior to this, she worked at F. Hoffmann-La Roche in Switzerland where she gained several years' experience in industry basics and pre-clinical research. Mónica has a Degree in Chemistry and Biochemistry from Basel University. Alan Chalmers Pharmacist Management Forum Dr Alan Chalmers is a pharmacist with over 35 industrial experiences mainly in the field of pharmaceutical regulatory affairs. A graduate of Strathclyde University in Glasgow with a B.Sc. in Pharmacy with specialisation in Pharmaceutical Technology, his Ph.D. at Manchester University was in Pharmaceutical Formulation. From 1975-1978 he was Development Officer and Clinical Trials Pharmacist of Allen & Hanburys (part of the then Glaxo group). In 1978 he joined Ciba-Geigy in DRA. Over 20 years were spent with Ciba-Geigy/CIBA/Novartis in all aspects of regulatory affairs including head of a group company DRA in Canada and for many years as Head of Pharma International regulatory affairs. He has been consultant to the IFPMA, WHO and other international bodies and was Chairman of the Organising Committee of the initial IFPMA Asian Regulatory Conferences in Hong Kong and Singapore and Rapporteur to the more recent conferences in China and Malaysia. Since 1998 he has been an independent regulatory consultant and is Director of his own consultancy company Pharma International in Switzerland. He has also been director of two UK and Swiss registered pharmaceutical companies with specialised responsibility for international regulatory strategy. More recently as accredited by Swissmedic, Dr. Chalmers is a Qualified Person supporting several Swiss pharmaceutical companies trading internationally with pharmaceuticals and medical devices. He is published, and his publications include a textbook on International Pharmaceutical Registration, Active Pharmaceutical Ingredients and as Swiss correspondent to the Regulatory Affairs Journals Pharma and Medtech. Since 2012 he has been a member of the Editorial Board, Scrip Regulatory Affairs. For more information about this conference visit https://www.researchandmarkets.com/r/smaxv9 About ResearchAndMarkets.com ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.

DUBLIN--( BUSINESS WIRE )--The "Excipients in Pharmaceuticals: Global Markets to 2029" report has been added to ResearchAndMarkets.com's offering. The Excipients in Pharmaceuticals Market was valued at USD 9.7 billion in 2024, and is expected to reach USD 12.4 billion by 2029, rising at a CAGR of 5.10%. This report provides a comprehensive summary of pharmaceutical excipients, along with a discussion of the competitive landscape and profiles of key market players that highlight revenues, product portfolios, and recent activities. The report analyzes trends and dynamics, including drivers, limitations, challenges and opportunities. This research study discusses historical, current and potential market size. The report will enable market players and new entrants to make informed decisions about the production and licensing of goods and services. Organizations, distributors and exporters will find useful information about market developments and trends. The report segments the market by three product types: organic, inorganic or water that meets the standards of the U.S. Pharmacopeia (USP). Regional and country-level market analysis is provided for all the major segments. The market is divided into segments as follows: By excipient material type: Organic Inorganic USP water By organic type: Carbohydrates Petrochemicals Oleochemicals Proteins Other organic excipients By inorganic type: Calcium salts Halites Metal oxides Silicates Other inorganic excipients By dosage form: Solid dosage form Liquid dosage form Semisolid dosage form Other dosage forms By administration route: Oral Injectable Topical Advanced drug delivery By end user: Pharmaceutical companies Contract formulators Research institutes Other end users For each area, for the base year of 2023, the analyst identified the current products in the market as well as market drivers; measured the current market size; quantified current company market shares; and made forecasts for 2029. The report includes: 73 data tables and 33 additional tables An overview of the global market for excipients in pharmaceuticals industry Analysis of global market trends, featuring historical revenue data from 2021 to 2023, estimated figures for 2024, and projected CAGRs through 2029 Evaluation of the current market's size and revenue growth prospects, along with a market share analysis by material, product type, dosage form, route of administration, end user and region A look at the innovations, technological advances, clinical trials, and recent product launches Analysis of the industry's regulatory framework and policies A discussion of ESG challenges and ESG practices in the industry An analysis of the key companies' market shares, proprietary technologies, strategic alliances and patents Profiles of the leading players in the excipients in pharmaceuticals market including ADM, BASF, Roquette Freres, Ashland Global, and Croda International. Key Attributes: Report Attribute Details No. of Pages 105 Forecast Period 2024 - 2029 Estimated Market Value (USD) in 2024 $9.7 Billion Forecasted Market Value (USD) by 2029 $12.4 Billion Compound Annual Growth Rate 5.1% Regions Covered Global Key Topics Covered: Chapter 1 Executive Summary Market Outlook Scope of Report Market Summary Chapter 2 Market Overview Role of Excipients in Pharmaceuticals Functions of Excipients Chapter 3 Market Dynamics Market Drivers Increasing Pharmaceutical and Biopharmaceutical Consumption Increasing Demand for Functional Excipients Increasing Demand for Novel Excipients Instant Sourcing of Excipients Market Restraints High Development Costs Lack of Independent Regulatory Body for Novel Excipients Stringent Pharmaceutical Regulations Market Opportunities Growing Demand for Biologics, Biosimilars and Specialty Drugs Market Challenges Supply Chain Disruptions Chapter 4 Emerging Technologies and Developments 3D Printing in Drug Formulations AI in Excipient Selection Novel Excipients Clinical Trials Selected Trials Chapter 5 Global Market for Pharmaceutical Excipients Segmentation Breakdown Market Breakdown by Material Type Organic Excipients Market, by Type Market for Inorganic Excipients, by Type Market for USP Water, by Type Market Breakdown by Dosage Form Market Breakdown by Route of Administration Market Breakdown by End User Market Breakdown by Region Market Breakdown by Product Regional and Country-level Markets for Organic Excipients Regional and Country-level Markets for Inorganic Excipients Chapter 6 Competitive Intelligence Industry Scenario Company Shares Competitive Landscape Chapter 7 Sustainability in the Market for Pharmaceutical Excipients: An ESG Perspective Introduction to ESG Concluding Remarks Company Profiles ADM Asahi Kasei Corp. Ashland BASF Croda International Evonik Industries Ingredion Kerry Group Roquette Freres For more information about this report visit https://www.researchandmarkets.com/r/7rwptq About ResearchAndMarkets.com ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.

With his extensive background in material science, biotechnology and production environments, Williamson set to lead company as CEO starting October 14 Modern Meadow continues to build its BIO-VERA® brand and expand production NUTLEY, N.J., Oct. 14, 2024 /PRNewswire/ -- Modern Meadow, a leader in sustainable materials, has announced that David Williamson, PhD, will transition from president and chief operating officer (COO) to chief executive officer (CEO), effective October 14, 2024. Dr. Williamson has served in multiple roles within the company since 2015 and will now spearhead its next phase of growth. As CEO, Dr. Williamson will continue executing on the company's strategic growth plan to create sustainable biofabricated materials that offer new levels of performance, sustainability and design possibilities. Continue Reading Dr. Williamson has served in multiple roles within Modern Meadow since 2015 and will now spearhead its next phase of growth as CEO. Post this With his extensive background in material science, biotechnology and production environments, Dr. Williamson will continue executing on Modern Meadow's strategic growth plan to create sustainable biofabricated materials that offer new levels of performance, sustainability and design possibilities, like BIO-VERA. "All of us at Modern Meadow have a passion for technology and innovation, and I am proud to lead us into our next chapter as we continue to advance our mission of commercializing transformative sustainable alternative materials, such as BIO-VERA," Dr. Williamson said. "Modern Meadow is at a pivotal stage – one in which we are building on our major production milestone to produce 500,000 square meters per year of our BIO-VERA. This milestone highlights the market readiness and cost-efficiency of BIO-VERA, positioning Modern Meadow to meet increasing demand from original equipment manufacturers (OEMs), brands and premium tanneries that are actively adopting the material." Modern Meadow's strategy includes: Streamlining operations for increased efficiency Expanding its European market presence Supporting commercialization and brand adoption efforts by extending its operational runway. The company will also continue to strengthen and expand the BIO-VERA brand by developing refreshed brand messaging, in close collaboration with its commercial partners, to bring the brand to life for consumers and industry alike. About Modern Meadow Modern Meadow is focused on creating innovative biomaterials that make a positive impact on the world. Its main product, BIO-VERA®, is a transformative new sustainable material that is not only beautiful, but stronger and lighter than traditional materials. Made with over 90% renewable carbon content, BIO-VERA is crafted using Bio-Alloy™, a flexible mix of proteins and polymers. This approach allows Modern Meadow to reduce reliance on oil-based and animal products without sacrificing quality. BIO-VERA is designed to easily integrate into existing production processes used by industries such as automotive, footwear, furniture and fashion accessories, making it a practical option for immediate use. Modern Meadow works closely with top brands like Tory Burch and industry leaders like BASF, Bader and ISA TanTec to ensure its products are of the highest quality and fully traceable from its lab to the brands people love. For more information, visit modernmeadow.com or follow the company on LinkedIn and Instagram. Media Contact Jordan Vines +1 (540) 629-3137 [email protected] BIO-VERA is a registered trademark of Modern Meadow, Inc. SOURCE Modern Meadow WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM? 440k+ Newsrooms & Influencers 9k+ Digital Media Outlets 270k+ Journalists Opted In GET STARTED